CXCR4 and breast carcinoma: Therefore, we would propose that treatment with CXCR4 antagonists such as AMD3100 in the perioperative period would prevent the migration and invasion of CXCR4 expressing breast cancer cells into organs of metastases that are rich in SDF1α.